8-K: Singular Genomics Acquired by Deerfield Management for $20 Per Share, Transitions to Private Company
Sentiment:
Merger Announcement
Singular Genomics Systems, Inc. has completed its acquisition by Deerfield Management Company, transitioning to a private company after satisfying customary closing conditions.
Capital raiseDeerfield Private Design Fund IV committed to provide a term loan to the Borrowers in an aggregate amount of up to $37.5 million.Proceeds from such loan in the amount of approximately $37 million were deposited with the paying agent under the Merger Agreement for further payment to the Company's stockholders pursuant to the Merger Agreement.
Summary
- Singular Genomics Systems, Inc. has been acquired by Deerfield Management Company's affiliate.
- The acquisition was completed on February 21, 2025, following a definitive agreement signed on December 22, 2024.
- Deerfield acquired all outstanding shares of Singular Genomics common stock not already owned by them for $20.00 per share in cash.
- The transaction was approved by Singular Genomics' stockholders on February 19, 2025.
- Singular Genomics will now operate as a private company.
- Trading of Singular Genomics common stock on Nasdaq has been suspended, and the company has requested delisting.
- Joshua Stahl has been appointed as the new Chief Executive Officer, replacing Andrew Spaventa.
- Jason Myers has joined the Board of Directors.
- Andrew Spaventa will continue to serve on the Board and as a special advisor to the CEO.
- Deerfield Private Design Fund IV provided a term loan of up to $37.5 million in connection with the merger.
- Approximately $37 million from the loan was used to pay Singular Genomics' stockholders.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive. The acquisition provides Singular Genomics with financial backing and flexibility as a private company. However, the delisting from Nasdaq and management changes introduce some uncertainty.
Positives
- The acquisition provides Singular Genomics with greater flexibility to advance its business strategy as a private company.
- Deerfield's support is expected to help Singular Genomics continue its work in providing crucial sequencing and multiomics information.
- Andrew Spaventa will continue to serve on the Board and as a special advisor to the CEO.
Negatives
- Trading of Singular Genomics common stock has been suspended on Nasdaq and Singular Genomics has requested that its common stock be delisted from Nasdaq.
- Former CEO Andrew Spaventa, Chief Scientific Officer Eli Glezer, and CFO Dalen Meeter have resigned from the company.
Risks
- The press release contains forward-looking statements that are subject to risks, uncertainties, and assumptions.
- Actual results could differ materially from the results implied by these forward-looking statements if risks materialize or assumptions prove incorrect.
- New risks emerge from time to time, and it is not possible for management to predict all risks.
Future Outlook
Singular Genomics will operate as a private company with greater flexibility to advance its business strategy, supported by Deerfield Management.
Management Comments
- Andrew ElBardissi, M.D., Partner at Deerfield, stated that they are pleased to support Singular Genomics during this important transition.
- Andrew ElBardissi, M.D., Partner at Deerfield, stated that they look forward to this new direction for the company and its technology as Singular continues its work to provide physicians and scientists with crucial sequencing and multiomics information.
Industry Context
The acquisition reflects a trend of investment firms acquiring life science companies to support their long-term growth and innovation in the next-generation sequencing and multiomics technologies space.
Comparison to Industry Standards
- The acquisition price of $20 per share is a key metric to compare with other acquisitions in the genomics and life sciences sector.
- Comparable companies in the NGS space include Illumina, Pacific Biosciences, and Oxford Nanopore Technologies.
- The $37.5 million term loan can be compared to debt financing structures of similar acquisitions in the industry.
- The transition to a private company is a strategic move seen in other technology companies aiming for long-term growth without the pressures of public markets.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer | Andrew Spaventa | Joshua Stahl | February 21, 2025 | Merger Agreement |
| President | N/A | Jason Myers | February 21, 2025 | Merger Agreement |
| Chief Scientific Officer | Eli Glezer, Ph.D. | N/A | February 21, 2025 | Resignation |
| Chief Financial Officer | Dalen Meeter | N/A | February 21, 2025 | Resignation |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Amendment to Articles of Incorporation | The Amended and Restated Certificate of Incorporation of the Company was amended and restated to be in the form of the certificate of incorporation set forth on Exhibit A to the Merger Agreement. | February 21, 2025 | Reflects the new ownership structure and governance of the company as a private entity. |
| Amendment to Bylaws | The Company's bylaws were amended and restated to be identical to the bylaws of Merger Sub, other than the name of Merger Sub, which was replaced by the name of the Company. | February 21, 2025 | Aligns the company's operational procedures with the new ownership and management structure. |
Related Party Transactions
- Deerfield Private Design Fund IV entered into a Credit Agreement with Parent and Merger Sub, providing a term loan of up to $37.5 million.
- Rollover Agreements were entered into by Parent and the Rollover Stockholders, pursuant to which certain of their respective Company Shares (Rollover Shares), restricted stock units of the Company (Company RSUs) or Company stock options (Company Options) converted into shares of Parent Company Shares held by Parent immediately prior to the Effective Time.
Stakeholder Impact
- Shareholders received $20 per share in cash for their shares.
- Employees may experience changes in roles and responsibilities due to the management transition.
- Customers and partners can expect continued development and support of Singular Genomics' products and technologies.
- The company's transition to a private entity may impact its relationships with suppliers and creditors.
Next Steps
- Singular Genomics will continue to operate as a private company.
- The company will focus on advancing its business strategy in next-generation sequencing and multiomics technologies.
- Joshua Stahl will lead the company as CEO, with guidance from Andrew Spaventa as a special advisor.
Key Dates
| Date | Description |
|---|---|
| June 3, 2016 | Singular Genomics Systems, Inc. was originally incorporated. |
| December 22, 2024 | Agreement and Plan of Merger was dated. |
| February 19, 2025 | Singular Genomics common stock holders voted to approve the transaction. |
| February 20, 2026 | The term loan is scheduled to mature. |
| February 21, 2025 | Merger completed, Singular Genomics becomes a wholly owned subsidiary of Parent, trading suspended on Nasdaq. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.